The Brain & Behavior Research Foundation (BBRF) has taken a pivotal step forward in advancing the understanding and treatment of mental health disorders by announcing a $1 million allocation in Distinguished Investigator Grants for 2026. These awards, handed out to ten senior scientists of international prominence, aim to support groundbreaking research probing the neurobiological and behavioral mechanisms underlying some of the most challenging psychiatric conditions. Backed by the WoodNext Foundation, these grants represent a significant injection of resources designed to propel mental health research into new, unexplored territories.
Each of the ten Distinguished Investigator Grants offers $100,000 for a one-year period, targeting projects that focus on a range of debilitating disorders such as depression, autism spectrum disorder (ASD), post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia, cocaine use disorder, and chronic cannabis use. This funding initiative is a vital component of WoodNext’s five-year $5 million commitment to BBRF’s programs, underscoring the priority placed on unearthing transformative insights into mental illness.
Jeffrey Borenstein, M.D., President and CEO of BBRF, emphasizes the urgency of these studies by highlighting the vast impact of mental illness globally and the persistent gaps in our biological understanding of these disorders. According to Dr. Borenstein, these grants facilitate research that challenges conventional paradigms, potentially redefining diagnostic criteria, enhancing monitoring techniques, and paving the way for innovative treatments that could significantly alter patient outcomes.
The WoodNext Foundation, led by Executive Director Nancy Chan, stresses the importance of supporting high-impact scientific endeavors that push the bounds of current knowledge. They believe that such bold research efforts are essential in unlocking novel therapeutic avenues and ultimately improving lives affected by mental health conditions.
Among the notable recipients, Dr. Ravi Allada from the University of Michigan is investigating the intricate biological interplay between bipolar disorder and the regulation of circadian rhythms and sleep. His work aims to identify biomarkers that could refine diagnosis and treatment – a thorough molecular mapping of risk genes to functional clinical phenotypes could revolutionize how the psychiatric community assesses and manages bipolar disorder, potentially integrating circadian-based therapeutic modalities such as timed light exposure and melatonin administration.
At Harvard University, Dr. Paola Arlotta leverages cutting-edge human brain organoid technology to model early developmental disruptions associated with ASD. By studying the asynchronous maturation of inhibitory neurons relative to their excitatory counterparts, her research delves into the cellular and circuit-level abnormalities that might underlie the diverse manifestations of autism across different genetic risk profiles. The project will test hypotheses regarding the neural circuitry disruption caused by mutations in genes such as ARID1b, deepening our understanding of ASD pathogenesis at a fundamental level.
Dr. Christopher W. Cowan from the Medical University of South Carolina is pioneering an RNA-based therapeutic approach to treat MEF2C haploinsufficiency syndrome (MCHS), a single-gene disorder with profound neurodevelopmental consequences including autism-like symptoms, language impairment, and seizures. His research not only sheds light on the molecular underpinnings of this rare but debilitating syndrome but also has broader implications for bipolar disorder, major depressive disorder, and schizophrenia, all of which show genetic correlation with MEF2C variants.
Addressing PTSD, Dr. Aline Desmedt at INSERM in France has innovated an animal model that accurately captures the dual facets of pathological trauma memory: traumatic hypermnesia and contextual amnesia. This critical distinction allows for a refined exploration of the neurobiological mechanisms regulating the transformation between normative fear memories and pathological trauma responses. Her work could illuminate novel targets for therapeutic intervention aimed at preventing or reversing the intrusive and debilitating memories characteristic of PTSD.
Cocaine use disorder (CUD) is the focus of Dr. Karen D. Ersche’s research at the University of Cambridge, where she investigates the role of neuroendocrine disruptions impacting decision-making and emotional regulation. This research explores how imbalances in the hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes influence brain regions such as the amygdala and orbitofrontal cortex. Understanding the link between hormonal dysregulation and maladaptive behaviors in CUD could herald new pharmacological or behavioral treatment strategies.
The intersection of gene expression and neuropsychiatric disorders is a frontier explored by Dr. Stephen J. Glatt at SUNY Upstate Medical University, who is developing BrainGENIE+, an advanced algorithm to non-invasively infer gene expression across multiple brain regions via blood samples. This methodological breakthrough promises not only to trace molecular dynamics during disease onset, progression, and recovery but also to establish comprehensive atlases of gene expression linked to brain health and pathology.
UCLA’s Dr. Alicia Izquierdo investigates the neurocircuitry underlying schizophrenia by dissecting how the brain distinguishes between environmental volatility—the rate at which external conditions change—and stochasticity, the random noise inherent in these conditions. Her focus on thalamo-frontocortical networks and their role in modulating these perceptions is expected to illuminate how impaired volatility processing contributes to paranoia and psychosis, offering new avenues for targeted neuromodulation therapies.
At the Medical University of South Carolina, Dr. Wei Jiang focuses on the paradoxical association of chronic cannabis use with anxiety, depression, and suicidality. His research zeroes in on the peripheral contributions to central nervous system dysfunction, particularly how alterations in the oral microbiome, specifically Actinomyces species, might drive mitochondrial dysfunction and disturbed neurotransmission, thus influencing emotional states in chronic users.
Dr. Loren L. Looger from UC San Diego explores an underappreciated pharmacological mechanism for antidepressant effects: the intracellular upregulation of serotonin synthesis. While selective serotonin reuptake inhibitors (SSRIs) act extracellularly, recent findings suggest psychedelics and MDMA may boost serotonin synthesis within neurons, enhancing therapeutic outcomes. Dr. Looger’s high-throughput screen aims to identify novel compounds that modulate this intracellular pathway, potentially revolutionizing antidepressant drug design beyond conventional modalities.
Finally, Dr. Jamie L. Maguire at Tufts University addresses the pressing issue of treatment-resistant depression by developing therapies targeting neurosteroid synthesis. These endogenous compounds possess documented anxiolytic and antidepressant properties, and by enhancing their biosynthesis, her team aims to craft transdiagnostic interventions with the potential to dramatically expand the therapeutic arsenal for psychiatric illnesses.
The BBRF and its Allied WoodNext Foundation collectively underscore a fundamental commitment: 100% of funds donated for research are reinvested exclusively into scientific projects, ensuring the most effective use of philanthropic resources. This model has empowered the Foundation to grant over $476 million to more than 5,700 investigators since 1987, fostering innovation and hope within the mental health community. Through sustained investment in high-risk, high-reward research, these grants propel the scientific community toward breakthroughs that could redefine mental health diagnostics, therapeutics, and ultimately, patient recovery worldwide.
Subject of Research: Neurobiological and behavioral research into major mental health disorders including depression, autism spectrum disorder, PTSD, bipolar disorder, schizophrenia, and substance use disorders.
Article Title: Brain & Behavior Research Foundation Awards $1 Million for Groundbreaking Mental Health Research in 2026
News Publication Date: Not specified
Web References:
– https://bbrfoundation.org/
– https://www.instagram.com/woodnext/
– https://www.pbs.org/show/healthy-minds-with-dr-jeffrey-borenstein/
Image Credits: BBRF
Keywords: Mental health, neurobiology, depression, autism spectrum disorder, PTSD, bipolar disorder, schizophrenia, cocaine use disorder, chronic cannabis use, circadian rhythms, gene expression, neurosteroids, serotonin synthesis, neuroendocrine dysregulation, brain organoids, RNA therapeutics
